TrialThe Journal of clinical investigation2024

Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes.

Ana Lledó-Delgado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.